New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

PD-L1 (Extracellular region) M080 Antibody

Applications

  • WB
  • IP
  • ICC

Reactivity

  • Human
Overview
Catalog # bsm-70604M
Product Name PD-L1 (Extracellular region) M080 Antibody
Applications WB, IP, ICC
Specificity Clone M080 mouse monoclonal antibody detects a 45-55 kDa* protein on SDS-PAGE "Native" or denatured immunoblots of human recombinant PD-L1 extracellular region, and human lung tissue. The antibody works for western blot, immunoprecipitation, immunocytochemistry, and ELISA capture.
Reactivity Human
Specifications
Conjugation Unconjugated
Host Mouse
Source Clone (M080) was generated from a recombinant protein that included the extracellular region of human PD-L1 protein.
Clonality Monoclonal
Clone # M080
Isotype IgG1
Purification Purified by Protein G.
Storage Buffer PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol
Storage Condition Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C.
Target
Swiss Prot Q9NZQ7
Synonyms Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, hPD-L1, B7 homolog 1, B7-H1, CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1
Background Programmed cell death 1 ligand 1 (PD-L1, B7-H1, CD274) is a member of the B7 family of cell surface ligands that regulate T cell activation and immune responses. The B7 family members have conserved regions that include extracellular IgV and IgC domains, and a short cytoplasmic region. Research studies demonstrate that PD-L1 is expressed in several tumor types, including melanoma, ovary, colon, lung, breast, and renal cell carcinomas. PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, which promotes tumor survival. The blockage of the PD1/PD-L1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy. Several therapies that target PD1/PD-L1 pathways are currently in use or in clinical trials
Application Dilution
WB 1:300-5000
IP 1-2ug
ICC 1:100-500